Endocyte, Inc. (ECYT) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Endocyte, Inc. (NASDAQ:ECYT) from a sell rating to a hold rating in a research report report published on Thursday.

According to Zacks, “Endocyte posted narrower-than-expected loss in the third quarter of 2017. In October 2017, the company accelerated its path to commercialization as it acquired the rights to PSMA-617, being evaluated for the treatment of prostate cancer. The candidate represents a more than $1 billion market opportunity and its development is now the main priority of the company. Currently, the company plans to focus on its most promising programs – lutetium PSMA-617 radioligand therapy and prostate cancer, and CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform. However, with no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth. So far this year, shares of the company have outperformed the industry.”

A number of other research analysts have also recently commented on ECYT. Cowen and Company restated a hold rating on shares of Endocyte in a research note on Monday, October 2nd. ValuEngine upgraded shares of Endocyte from a strong sell rating to a sell rating in a research note on Monday, October 2nd. Finally, Wedbush upgraded shares of Endocyte from a neutral rating to an outperform rating and lifted their target price for the company from $2.00 to $7.00 in a research note on Tuesday, October 3rd.

Endocyte (NASDAQ:ECYT) traded up $0.15 during mid-day trading on Thursday, reaching $5.33. The company had a trading volume of 1,108,400 shares, compared to its average volume of 1,236,905. Endocyte has a fifty-two week low of $1.17 and a fifty-two week high of $6.55.

Endocyte (NASDAQ:ECYT) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The business had revenue of $0.03 million for the quarter. Endocyte had a negative return on equity of 38.91% and a negative net margin of 82,235.72%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the company posted ($0.21) EPS. analysts anticipate that Endocyte will post -1.24 EPS for the current year.

WARNING: “Endocyte, Inc. (ECYT) Upgraded to Hold at Zacks Investment Research” was first published by Markets Daily and is the property of of Markets Daily. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/13/endocyte-inc-ecyt-upgraded-to-hold-at-zacks-investment-research.html.

Large investors have recently bought and sold shares of the company. Ameriprise Financial Inc. raised its stake in shares of Endocyte by 26.7% in the first quarter. Ameriprise Financial Inc. now owns 133,270 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 28,110 shares during the last quarter. FMR LLC raised its position in Endocyte by 0.7% in the 1st quarter. FMR LLC now owns 3,509,035 shares of the biopharmaceutical company’s stock worth $9,018,000 after purchasing an additional 24,625 shares during the last quarter. Parametric Portfolio Associates LLC raised its position in Endocyte by 57.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 162,329 shares of the biopharmaceutical company’s stock worth $417,000 after purchasing an additional 59,454 shares during the last quarter. Bank of New York Mellon Corp raised its position in Endocyte by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 6,469 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Endocyte by 1,064.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 393,975 shares during the last quarter. Institutional investors own 25.58% of the company’s stock.

About Endocyte

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply